U.S. Online Retail and Ecommerce Stock News

NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump?

Corvus Pharmaceuticals (CRVS) has drawn investor interest after recent share price moves, with the stock last closing at $13.05 and a market value of about $1.09b. This highlights heightened attention on this clinical stage biopharma. See our latest analysis for Corvus Pharmaceuticals. Recent momentum in Corvus Pharmaceuticals has been strong, with a 7 day share price return of 9.57% and a year to date share price return of 78.28%. The 1 year total shareholder return of 209.98% points to a...
NasdaqGS:CBRS
NasdaqGS:CBRSSemiconductor

Cerebras Systems (CBRS) Is Down 28.2% After AI Mega‑Deals Shift Model Toward Lower‑Margin Cloud

Cerebras Systems’ first post-IPO earnings report in June 2026 showed Q1 revenue rising to US$193.41 million, a narrower net loss of US$14.01 million, and new multi‑year AI infrastructure agreements with OpenAI and Amazon Web Services worth more than US$20 billion in aggregate. The company’s plan to lease back data center capacity as it pivots from selling chips to running an AI cloud points to a trade‑off between securing long‑term compute contracts and accepting lower gross margins in the...
NasdaqGS:ADPT
NasdaqGS:ADPTLife Sciences

Does Adaptive Biotechnologies’ (ADPT) Convertible Raise and Split Plan Reveal a New Strategic Center of Gravity?

Earlier in June 2026, Adaptive Biotechnologies completed a US$300,000,000 zero-coupon, senior unsecured convertible notes offering due July 1, 2031, shortly after announcing plans to separate its Minimal Residual Disease and Immune Medicine businesses and evaluate alternatives for the Immune Medicine unit. This combination of a planned business separation and fresh convertible funding highlights Adaptive’s effort to refine its business focus while bolstering financial flexibility for future...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In

Catalyst Pharmaceuticals (CPRX) has drawn investor attention after its rare-disease portfolio produced annual revenue of $596.958 million and net income of $221.323 million, putting the current share price of $31.42 into sharper focus. See our latest analysis for Catalyst Pharmaceuticals. Over the past year, Catalyst Pharmaceuticals has coupled solid reported profitability with strong momentum, with a 1-year total shareholder return of 43.54% and a 5-year total shareholder return of 442.66%...
NasdaqGS:RGLD
NasdaqGS:RGLDMetals and Mining

How Royal Gold’s Hod Maden Stake-for-Royalty Swap At Royal Gold (RGLD) Has Changed Its Investment Story

Royal Gold Inc. recently restructured its interest in the Hod Maden gold-copper project in Türkiye, cutting its joint-venture equity stake from 30% to 15% while securing a new 2.5% net smelter return royalty as Lidya Madençilik assumes full operatorship and SSR Mining exits for a 4.0% royalty. This shift from direct ownership toward a larger royalty emphasis at Hod Maden highlights Royal Gold’s preference for lower-operational-risk income streams over project-level control. We’ll now examine...
NasdaqGS:CVBF
NasdaqGS:CVBFBanks

June 2026's Top Value Stocks With Estimated Discounted Valuations

Over the last 7 days, the United States market has experienced a 2.7% decline, yet it remains up 19% over the past year, with earnings projected to grow by 18% annually in the coming years. In this context of fluctuating short-term performance and strong long-term growth expectations, identifying undervalued stocks with discounted valuations can be an effective strategy for investors seeking to capitalize on potential market opportunities.
OTCPK:INVU
OTCPK:INVUSoftware

3 Promising Penny Stocks With Market Caps Under $500M

Over the last 7 days, the market has dropped 2.7%, contrasting with a 19% rise over the past year, and earnings are forecast to grow by 18% annually. In such a landscape, identifying stocks with strong financials becomes crucial for investors looking to capitalize on growth opportunities. While the term 'penny stocks' might seem outdated, these smaller or newer companies can offer unique value and growth potential when backed by solid fundamentals.
NasdaqGS:MYFW
NasdaqGS:MYFWBanks

3 Growth Companies With High Insider Ownership Seeing 71% Earnings Growth

Over the last 7 days, the United States market has experienced a 2.7% drop, yet it remains up by 19% over the past year with expectations of an 18% annual earnings growth in the coming years. In this context, identifying growth companies with high insider ownership can be particularly appealing as they often align management interests with shareholders and may indicate confidence in future performance.
NasdaqCM:IGIC
NasdaqCM:IGICInsurance

International General Insurance Holdings And 2 Other Reliable Dividend Stocks For Your Portfolio

In the United States market, recent fluctuations have seen a 2.7% drop over the last week, yet it has achieved a notable 19% increase over the past year with earnings expected to grow by 18% annually. In such dynamic conditions, selecting reliable dividend stocks like International General Insurance Holdings can offer stability and potential income for investors seeking to balance growth with consistent returns.
NYSE:AVB
NYSE:AVBResidential REITs

AvalonBay Communities (AVB) Regains Momentum, Is The Stock Still Cheap?

AvalonBay Communities (AVB) has drawn investor attention after recent trading, with the stock last closing at US$186.13. The move has prompted closer scrutiny of its performance, valuation signals and underlying apartment-focused business. See our latest analysis for AvalonBay Communities. Recent trading suggests momentum around AvalonBay Communities is improving, with a 1-day share price return of 1.38% and a 90-day share price return of 15.75%, even though the 1-year total shareholder...
NasdaqGM:ISTR
NasdaqGM:ISTRBanks

3 Low Volatility Stocks For Investors Rethinking U.S. Market Risk

With veteran investor Jeremy Grantham flagging U.S. stocks as extremely expensive based on the Buffett indicator, many investors are rethinking how much risk they really want in their portfolios. While the artificial intelligence boom has pushed market valuations higher and stirred talk of a possible bubble, some larger companies with historically low share price volatility and solid balance sheets may offer a different way to stay invested. This article looks at 3 stocks from our Low...
NYSE:AA
NYSE:AAMetals and Mining

Does Alcoa (AA) Securing Long-Term Union Contracts Clarify Its Cost Structure Or Cloud Its Flexibility?

Alcoa Corporation recently announced that United Steelworkers union members ratified a new labor agreement covering about 965 employees at its Warrick (Indiana) and Massena (New York) smelters, effective from May 16, 2026, through May 15, 2030. This multi-year contract reduces the risk of labor disruption at two important U.S. smelters, offering greater visibility into Alcoa’s near-term operating continuity and cost planning. We’ll now examine how this newly ratified multi-year labor...
NYSE:ED
NYSE:EDIntegrated Utilities

Consolidated Edison (ED) Faces A Valuation Test Following Mizuho Downgrade

Mizuho’s decision to downgrade Consolidated Edison (ED) to Neutral, citing constrained growth prospects and a less compelling valuation discount versus peers, has drawn fresh attention to the stock’s current pricing and risk profile. See our latest analysis for Consolidated Edison. Despite the recent Mizuho downgrade and earlier cautious commentary from Morgan Stanley, Consolidated Edison’s share price is at $110.76, with a year-to-date share price return of 10.77% and a 1-year total...
NYSE:MAS
NYSE:MASBuilding

Masco (MAS) Is Up 7.2% After Q1 Earnings Beat And Sector Strength - Has The Bull Case Changed?

Earlier this year, Masco reported a strong first quarter, with revenues surpassing analyst expectations and solid organic revenue and EBITDA growth across its home improvement portfolio. This performance came as the broader home construction materials sector also delivered better-than-expected results and guidance, reinforcing Masco’s exposure to a healthier-than-anticipated repair and remodeling backdrop. We’ll now examine how this earnings outperformance and sector strength could influence...
NasdaqGM:PSNY
NasdaqGM:PSNYAuto

Polestar (PSNY) Faces U.S. Sales Ban From 2027 As Europe Takes Center Stage

Polestar Automotive Holding UK (NasdaqGM:PSNY) has been denied authorization to sell new vehicles in the U.S. from 2027 under upcoming connected vehicle regulations. The U.S. Department of Commerce cited national security concerns tied to Chinese technology in its decision. Polestar plans to shift its future focus toward European markets as access to new U.S. vehicle sales is restricted. Polestar Automotive Holding UK, listed as NasdaqGM:PSNY, develops and sells premium electric vehicles, a...
NasdaqGS:MBLY
NasdaqGS:MBLYAuto Components

Mobileye Global (MBLY) Is Down 7.1% After Launching Fully Owned U.S. Robotaxi Business Plan

In June 2026, Mobileye Global announced plans to expand beyond supplying self-driving technology by launching a fully owned, vertically integrated autonomous ride-hailing business in a major U.S. city from 2027, starting with about 100 robotaxis and aiming to scale materially over the following five years. This move shifts Mobileye closer to an end‑to‑end mobility operator, combining its Mobileye Drive system with Moovit’s massive user base and global multimodal mobility platform into a...
NYSE:IBM
NYSE:IBMIT

IBM (IBM) Stock After Mixed Returns And AI Cloud Growth Narrative

Short-term traders and long-term holders alike may be asking the same question about International Business Machines right now: is the current share price giving you fair value for the risk you are taking? Over the past week the stock gained 3.7%, and it is up 3.0% over the last month, even though the year to date return is down 11.4% and the 1 year return is down 9.3%, compared to a much stronger 112.2% return over 3 years and 123.9% over 5 years. Recent headlines around International...
NYSE:BRO
NYSE:BROInsurance

Brown & Brown (BRO) Wins 2026 Workplace Honors For Mental Wellness Focus

Brown & Brown (NYSE:BRO) has been recognized in 2026 for its workplace culture and mental health programs. The company was named to the Best Workplaces in Financial Services & Insurance and Best Workplaces for Mental Wellness lists. It also received the Platinum Level Bell Seal for Workplace Mental Health for the fourth consecutive year. Brown & Brown, trading at $60.83, is drawing attention for company culture as much as for its role in the insurance sector. The stock has risen 2.9% over...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

Aurinia (AUPH) Expands Autoimmune Pipeline With Zetomipzomib – Is Its Dependence On Lupkynis Fading?

Aurinia Pharmaceuticals recently highlighted progress in broadening its autoimmune portfolio, advancing aritinercept in clinical development and integrating Kezar Life Sciences’ zetomipzomib program following its acquisition. This move shifts Aurinia’s story from dependence on Lupkynis alone toward a more diversified pipeline that could reshape its long-term autoimmune footprint. We’ll now consider how this broadened autoimmune pipeline, particularly the addition of zetomipzomib, may...
NYSE:UHS
NYSE:UHSHealthcare

Is Universal Health Services (UHS) Undervalued As Its Behavioral Health Story Faces Share Price Pressure?

Recent Share Performance and Business Profile Universal Health Services (UHS) has not been tied to a specific fresh headline event, but the stock’s recent performance and business mix across acute care and behavioral health services give investors several data points to assess. The company operates hospitals and behavioral health facilities across the United States, with revenue of about $17.76b and net income of roughly $1.52b, supported by both Acute Care Hospital Services and Behavioral...
NYSE:ENS
NYSE:ENSElectrical

EnerSys (ENS) After EZSelect Lite Launch Has Its Valuation Story Changed

EnerSys (ENS) has drawn investor attention after launching its EZSelect Lite battery room management system in Switzerland, aiming to automate battery selection and monitoring for industrial users and address inefficiencies in large fleet operations. See our latest analysis for EnerSys. The EZSelect Lite launch lands as EnerSys trades at US$226.34 per share, with a 1 day share price return of 3.38%, a 90 day share price return of 32.08% and a 1 year total shareholder return of 164.17%...
NYSE:STZ
NYSE:STZBeverage

Constellation Brands (STZ) Could Be 18% Undervalued Following Mixed Earnings Expectations

Mixed expectations ahead of Constellation Brands earnings Constellation Brands (STZ) is back in focus as investors look ahead to its upcoming first quarter fiscal 2027 earnings release, with forecasts pointing to modest profit growth but softer expectations after recent EPS estimate revisions. See our latest analysis for Constellation Brands. Constellation Brands shares recently moved up with a 1-day share price return of 1% and a 7-day share price return of 2.32%, although the 1-year total...
NYSE:LEG
NYSE:LEGConsumer Durables

Is Leggett & Platt (LEG) Undervalued After Its Mid Class Massage System Launch?

Leggett & Platt (LEG) is back on investors’ radar after its Leggett Dynamics subsidiary launched the Mid-Class Massage System, a non-electronic massage solution now in production with a global automaker and shortlisted for a 2026 industry award. See our latest analysis for Leggett & Platt. That launch comes as Leggett & Platt’s short term momentum has picked up, with a 30 day share price return of 12.62% and a 90 day share price return of 21.09%, while the 1 year total shareholder return of...
NasdaqGS:MYRG
NasdaqGS:MYRGConstruction

MYR Group (MYRG) Draws Fresh Analyst Support, Is The Upside Already Priced In?

Recent interest around MYR Group (MYRG) picked up after Oppenheimer initiated coverage with a Perform rating, highlighting growth opportunities in electrical transmission, data centers, and complex infrastructure, along with stronger free cash flow and insider selling concerns. See our latest analysis for MYR Group. At a share price of $487.33, MYR Group has seen momentum build, with a 3.67% 1 day share price return, 78.20% over 90 days and a 1 year total shareholder return of 170.44%. If you...